Select Bibliography

Filter by any of these (after searching):

Hubbard, J. M.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

Mahoney, M. R. , Sloan, J. A. , Hubbard, J. M. , Liu, H. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147

A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.

Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - ASCO - J Clin Oncol - 2012

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database.

Shi, Q. , Hubbard, J. M. , Yothers, G. A. , Andre, T. , Saltz, L. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0441

Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147

Sloan, J. A. , Mahoney, M. R. , Sargent, D. J. , Hubbard, J. M. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary - Primary - Health Outcomes - NCCTG-N0147